SPHINX |
Catalog No.GC65981 |
SPHINX es un inhibidor selectivo de SRPK1 con un valor IC50 de 0,58 μM. SPHINX reduce eficazmente la neovascularizaciÓn coroidea (CNV) in vivo. SPHINX se puede utilizar para la investigaciÓn de (degeneraciÓn macular relacionada con la edad) AMD.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 848057-98-7
Sample solution is provided at 25 µL, 10mM.
IC50: 0.58 μM (SRPK1)[1]
SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1].
SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1].
SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1].
Western Blot Analysis[1]
Cell Line: | ARPE-19 cell line |
Concentration: | 10 μM |
Incubation Time: | 2 hours |
Result: | Blocked EGF-induced phosphorylation of SRSF1 and SRSF2. |
SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1].
SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1].
Animal Model: | C57/B6 mice with laser-induced CNV[1] |
Dosage: | 10 ng |
Administration: | Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7 |
Result: | Significantly reduced neovascular growth compared with saline-injected controls. |
Animal Model: | Norway Brown rats with laser-induced choroidal neovascularization[1] |
Dosage: | 25 ng (10 ng/uL) |
Administration: | Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7 |
Result: | Significantly reduced the CNV area compared with saline injected controls. |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *